U.S. Regulators Beef Up Investigation of Corporate Bribery & Corruption Overseas
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up investigations of corporate corruption and bribery abroad
You may also be interested in...
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm